Luina Bio is pleased to announce several expansion plans to meet the increasing demand in the microbiome and recombinant biopharma markets.
The first stage of the expansion will see Luina open additional small scale (30L) GMP manufacturing suite in late 2020, broadening the company’s service offering for new clinical projects that need small scale GMP facilities. This facility will be available to customers in Q3 2020 and has already generated interest from Luina Bio clients.
This will be followed by the opening of four additional development laboratories in late 2020, allowing Luina to take customer projects from the earliest development stage to a volume of 500L. This opening formally introduces the Company’s systems approach to facility design and utilisation, known as the Luina Flexible Manufacturing Platform (Luina FMP™).
The Luina FMP™ environment is designed to deliver the speed and technical excellence necessary to handle the development of technically advanced microbiome & recombinant protein projects. It capitalises on years of experience Luina Bio has growing bacteria initially thought to be unable to be grown at useful quantities for customers.